Andrographis Paniculata Extract Market Size, Share & Trends Analysis Report By Product (Less than 15%, 15%-50%, 50%-98%), By Applications (Hypoglycemic, Analgesic, Treatment of Dysentery, Treatment of Influenza, Other), By End Use, By Region, and Segment Forecasts - 2035

Andrographis Paniculata Extract Market Overview

The global andrographis paniculata extract market size was valued at USD 154.88 million in 2025 and is projected to grow from USD 170.37 million in 2026 to USD 226.77 million by 2035, at a CAGR of 10% from 2026 to 2035.

The Andrographis Paniculata Extract Market is expanding as botanical ingredient manufacturers, formulation companies, healthcare-product developers, and herbal processing businesses increase demand for standardized plant extracts with controlled concentrations of active compounds. The 15%-50% category is estimated to account for approximately 46.8% of product demand in 2026 because its concentration profile supports broad formulation flexibility while balancing processing efficiency, standardization, and ingredient compatibility. The 50%-98% category represents approximately 32.7%, while Less than 15% accounts for approximately 20.5%. Treatment of Influenza is estimated to represent approximately 30.6% of application demand, followed by Analgesic at approximately 22.8%, Treatment of Dysentery at approximately 18.1%, Hypoglycemic at approximately 16.7%, and Other at approximately 11.8%. Manufacturers increasingly focus on extraction efficiency, solvent recovery, controlled drying, chromatography, botanical traceability, microbial control, and batch consistency. Modern standardized extraction processes can improve target-compound concentration by more than 20% compared with basic unoptimized extraction, while multi-stage purification can raise final botanical purity to above 90% for selected high-concentration products.

The United States represents an important Andrographis Paniculata Extract Market because botanical supplements, natural ingredient formulations, functional wellness products, contract manufacturing, and specialty herbal distribution create recurring demand for standardized extracts. The 15%-50% category is estimated to account for approximately 48.2% of U.S. demand in 2026, followed by 50%-98% at approximately 34.1% and Less than 15% at approximately 17.7%. Treatment of Influenza represents approximately 31.8% of national application demand, while Analgesic contributes approximately 23.4%, Treatment of Dysentery approximately 15.2%, Hypoglycemic approximately 17.6%, and Other approximately 12.0%. U.S. buyers increasingly require botanical identity verification, contaminant testing, standardized active-compound profiles, and documentation across more than 5 quality parameters before ingredient acceptance. High-concentration extracts are gaining attention among manufacturers seeking smaller dosage volumes and more consistent formulation performance, while supply contracts increasingly emphasize traceability from plant cultivation through extraction and final packaging.

• 

  Download Free sample to learn more about this report.

Key Findings

• Leading Product Type: 15%-50% extracts are expected to lead with approximately 46.8% market share in 2026 because they balance standardized active-compound content, formulation flexibility, processing efficiency, and broad application compatibility.
• Leading Application: Treatment of Influenza is estimated to account for approximately 30.6% of 2026 demand as botanical formulations increasingly incorporate standardized Andrographis Paniculata Extract in seasonal wellness applications.
• Leading Region: Asia-Pacific is estimated to represent approximately 48.7% of global demand in 2026, supported by established cultivation, extraction capacity, traditional botanical use, and expanding ingredient manufacturing.
• Fastest Growing Region: North America is projected to expand at approximately 11.6% annually through 2035 as standardized botanical ingredients gain broader adoption across specialty formulations and natural-product manufacturing.
• Technology Trend: Advanced purification can raise selected high-concentration extracts above approximately 90% purity, improving batch consistency, formulation control, analytical repeatability, and premium ingredient positioning.
• Market Driver: Optimized extraction processes can improve target-compound recovery by approximately 20%, strengthening manufacturing efficiency and supporting standardized production across multiple Andrographis Paniculata Extract concentration levels.
• Competitive Landscape: The supplied competitive landscape includes 16 companies, intensifying competition around standardization, extraction yield, traceability, purification, quality testing, capacity expansion, and international ingredient distribution.
• Future Outlook: The 50%-98% category is expected to approach approximately 38.4% of product demand by 2035 as higher-standardization formulations and concentrated botanical ingredients gain wider commercial acceptance.

Latest Trends

Standardization is one of the strongest trends shaping the Andrographis Paniculata Extract Market as manufacturers seek more predictable active-compound concentrations and improved batch-to-batch consistency. The 15%-50% category accounts for approximately 46.8% of 2026 demand because it provides a practical balance between concentration and formulation flexibility. Buyers increasingly specify assay targets rather than accepting generic powdered extracts with uncertain composition. Processing facilities therefore use multiple analytical checkpoints covering botanical identity, active-compound concentration, moisture, microbial limits, residual solvents, and heavy-metal control. A commercial batch may undergo more than 6 quality checks before release. High-performance extraction systems also increasingly combine controlled solvent ratios, temperature management, filtration, concentration, and vacuum drying to reduce thermal degradation and improve yield. These manufacturing improvements are enabling suppliers to provide more consistent products to formulation companies operating across diverse applications.

Higher-concentration extracts are another important market trend. The 50%-98% category represents approximately 32.7% of 2026 demand and is gaining share as manufacturers seek smaller ingredient volumes and more precise formulation control. Multi-stage purification can increase target-compound concentration above approximately 90% for selected grades, reducing the amount of carrier material required in downstream products. This is especially useful where formulation space is limited or where companies seek standardized botanical profiles across different production batches. Chromatographic purification, membrane concentration, resin adsorption, and controlled crystallization are increasingly incorporated into advanced processing lines. At the same time, buyers are placing greater emphasis on raw-material origin because plant chemistry can vary with climate, harvest time, soil conditions, and drying methods. Supply contracts increasingly require cultivation and harvesting documentation across at least 3 traceability stages before extraction begins.

Market Dynamics

Driver

""Rising demand for standardized botanical ingredients is accelerating market expansion.""

The principal driver of the Andrographis Paniculata Extract Market is increasing demand for botanical ingredients with measurable active-compound content. Treatment of Influenza accounts for approximately 30.6% of 2026 application demand, reflecting significant use of Andrographis-based formulations in seasonal wellness and traditional botanical applications. Standardized extracts provide manufacturers with greater control than untreated herb powders because active-compound concentration can be quantified before formulation. A standardized ingredient containing 30% target compounds can offer substantially more predictable dosage calculations than a raw powder with highly variable composition. This predictability supports commercial manufacturing, quality documentation, and repeated production across multiple batches.

Improved extraction technology further strengthens market growth. Optimized processes can improve target-compound recovery by approximately 20% compared with less controlled methods, increasing output from the same quantity of botanical raw material. Manufacturers increasingly control temperature, extraction time, solvent ratio, pH, and drying conditions to maximize yield while protecting sensitive compounds. The 15%-50% category particularly benefits because manufacturers can achieve commercial standardization without the additional processing intensity required for very high purity. As botanical-product companies become more sophisticated, demand increasingly shifts toward extracts supported by documented assay results and traceable manufacturing.

Restraint

""Raw-material variability and quality-control requirements can constrain consistent production.""

Natural variation in Andrographis Paniculata raw material remains a major restraint because active-compound concentrations can differ depending on plant genetics, growing conditions, harvest maturity, drying, and storage. A variation of approximately 15% in incoming botanical potency can materially change extraction yield and final standardization requirements. Manufacturers may therefore need to blend several raw-material lots before processing to achieve more consistent input chemistry. This adds complexity to inventory management and requires analytical testing before extraction begins. Less than 15% products, representing approximately 20.5% of 2026 demand, are somewhat less sensitive to high-purity specifications, but even these products require consistent identity and contaminant control.

Quality-control costs also restrain smaller suppliers. Commercial customers increasingly expect testing across more than 5 parameters, including assay concentration, microbiological limits, moisture, residual solvents, and heavy metals. High-concentration grades may require additional chromatographic testing to verify chemical profiles. A producer running 20 batches per month can therefore perform hundreds of individual laboratory analyses. Suppliers without in-house laboratories must outsource these procedures, extending lead times and increasing operating costs. Market participation increasingly favors companies capable of integrating extraction, quality assurance, documentation, and traceability into one controlled manufacturing system.

Opportunity

""High-purity extracts and international botanical demand create substantial growth potential.""

The 50%-98% category represents a major market opportunity because demand is expected to increase from approximately 32.7% of product activity in 2026 to approximately 38.4% by 2035. High-concentration ingredients can reduce formulation volume while improving standardization, making them attractive for specialized botanical formulations. Advanced purification systems can achieve concentrations above approximately 90%, allowing suppliers to differentiate their products on assay strength and consistency. Companies investing in chromatography, resin purification, membrane filtration, and controlled crystallization can therefore access higher-value formulation requirements while reducing dependence on low-concentration commodity competition.

North America provides another significant opportunity and is projected to expand at approximately 11.6% annually through 2035. U.S. manufacturers increasingly require documented botanical identity and repeatable analytical profiles, creating opportunities for suppliers with strong quality systems. A vendor capable of providing certificates covering more than 6 analytical parameters can differentiate itself from basic bulk extract suppliers. Application diversification also supports growth because Hypoglycemic, Analgesic, Treatment of Dysentery, Treatment of Influenza, and Other collectively create multiple demand pathways rather than dependence on one formulation category. International distributors increasingly seek suppliers capable of producing multiple concentration grades from one validated botanical supply chain.

Challenge

""Maintaining standardized active-compound levels across natural harvest cycles remains difficult.""

The central technical challenge is maintaining consistent extract chemistry despite natural variation in plant material. Andrographis Paniculata harvested from different growing regions or seasons can show meaningful differences in active-compound concentration. If incoming plant material changes by approximately 10% in assay strength, extraction parameters may need adjustment to maintain the same final product specification. Manufacturers therefore require frequent raw-material testing and process controls. This challenge becomes particularly important in the 50%-98% category because high-purity products have tighter composition requirements and less tolerance for variation.

Scaling laboratory extraction into industrial production creates another challenge. A method that performs consistently with 10 kilograms of plant material may behave differently when scaled to several tonnes because heat transfer, mixing, filtration, and solvent recovery become more complex. Commercial plants therefore monitor multiple process variables and may require more than 4 purification stages for high-concentration products. Maintaining efficiency while controlling solvent residues, microbial quality, color, moisture, and assay strength requires careful process validation. Manufacturers that expand capacity without equivalent quality-control investment risk producing inconsistent batches and losing customer confidence.

• 

  Download Free sample to learn more about this report.

Segmentation Analysis

By Types

Less than 15%: Less than 15% extracts account for approximately 20.5% of market demand in 2026. These products are generally less processing-intensive than higher-concentration grades and can be suitable where broad-spectrum botanical composition is preferred over maximum active-compound purity. Manufacturing typically requires fewer purification stages, helping reduce processing complexity. A lower-concentration extract may preserve a wider range of naturally occurring plant constituents while still providing standardized botanical material. The segment remains relevant across cost-sensitive and traditional formulation requirements, although its market share is expected to decline gradually as demand shifts toward more standardized concentrated ingredients.

15%-50%: The 15%-50% category leads with approximately 46.8% market share in 2026 because it provides balanced concentration, formulation flexibility, manufacturing efficiency, and commercial standardization. Extracts within this category can be produced through controlled solvent extraction followed by concentration and drying without always requiring the multiple purification steps associated with very high-purity grades. Manufacturers often target standardized assay values such as 20%, 30%, or 40% depending on customer specifications. The category is expected to remain the largest through 2035 because it serves a broad range of Hypoglycemic, Analgesic, Treatment of Dysentery, Treatment of Influenza, and Other formulations.

50%-98%: The 50%-98% category accounts for approximately 32.7% of 2026 demand and is expected to approach approximately 38.4% by 2035. These extracts require advanced purification and tighter analytical control because manufacturers target high concentrations of specific active compounds. Multi-stage processing may involve more than 4 operations, including extraction, filtration, adsorption, concentration, purification, and drying. High-purity products are attractive where formulation space is limited or where customers require precise compound levels. The segment offers strong differentiation potential but also requires greater capital investment and quality-control capability.

By Applications

Hypoglycemic: Hypoglycemic applications account for approximately 16.7% of market demand in 2026. This segment uses standardized Andrographis Paniculata Extract within botanical formulations positioned around metabolic wellness and related traditional applications. Manufacturers increasingly prefer extracts with defined active-compound levels because formulation consistency is important when products are produced across multiple batches. The 15%-50% category is particularly relevant because it provides standardized concentration without excessive purification cost. Commercial buyers can specify assay tolerances within approximately 5% of target levels depending on product requirements.

Analgesic: Analgesic applications represent approximately 22.8% of 2026 demand. Botanical formulation companies use Andrographis Paniculata Extract in products associated with traditional pain-support applications and broader herbal combinations. Standardization improves consistency because manufacturers can calculate ingredient quantities based on measured compound concentration. A formulation using a 30% extract can require materially less ingredient mass than one using a lower-concentration product. The category therefore supports demand for both 15%-50% and 50%-98% products depending on formulation design and target positioning.

Treatment of Dysentery: Treatment of Dysentery accounts for approximately 18.1% of application demand in 2026. Traditional botanical use supports continued demand across markets where Andrographis Paniculata has established cultural familiarity. Manufacturers serving this application increasingly emphasize microbial control because botanical extracts used in digestive-related formulations must meet strict quality specifications. Production batches commonly undergo at least 3 microbiological checks covering total microbial count and specific contaminant limits. Standardized extracts help commercial producers maintain repeatable product profiles across different harvest seasons.

Treatment of Influenza: Treatment of Influenza leads with approximately 30.6% of 2026 application demand. Seasonal wellness formulations represent an important use area for standardized Andrographis Paniculata Extract, particularly where botanical products are well established. Demand can increase during periods of heightened respiratory-season purchasing, requiring suppliers to maintain sufficient inventory ahead of peak periods. A manufacturer may build more than 2 months of extract inventory before anticipated seasonal demand. The 15%-50% category is widely suited to this application because it balances concentration and cost while allowing flexible formulation with other botanical ingredients.

Other: Other applications represent approximately 11.8% of market demand in 2026 and include additional botanical uses beyond the 4 principal supplied application categories. Demand within this segment supports diversified extract portfolios because formulation companies may require different concentration levels according to product design. Some customers purchase quantities below approximately 100 kilograms for specialized formulation programs, while large manufacturers can contract significantly higher volumes. The category provides opportunities for suppliers capable of flexible batch manufacturing and multiple assay specifications.

• 

  Download Free sampleto learn more about this report.

Regional Outlook

North America

North America accounts for approximately 20.8% of global market demand in 2026 and is projected to expand at approximately 11.6% annually through 2035, making it the fastest-growing region. The United States dominates regional consumption through botanical supplements, specialty ingredient distribution, natural formulations, and contract manufacturing. The 15%-50% category accounts for approximately 48.2% of U.S. demand, while 50%-98% represents approximately 34.1%. Treatment of Influenza contributes approximately 31.8% of national application demand.

Quality documentation is particularly important in North America. Buyers increasingly request testing across more than 6 parameters before approving botanical ingredients. This creates opportunities for suppliers with strong analytical laboratories, traceability, and standardized manufacturing. High-purity extracts are gaining market share because manufacturers seek concentrated ingredients for compact formulations. North American demand through 2035 is expected to be driven by premium standardization, transparent sourcing, advanced quality documentation, and greater adoption of botanical ingredients across specialized formulations.

Europe

Europe represents approximately 18.9% of global Andrographis Paniculata Extract Market demand in 2026. Germany, France, the United Kingdom, Italy, and other mature botanical-product markets support demand through herbal formulations, ingredient distributors, and specialty wellness companies. The 15%-50% category represents approximately 45.7% of regional demand, while 50%-98% contributes approximately 35.8%. Treatment of Influenza accounts for approximately 29.4% of applications.

European buyers increasingly emphasize botanical traceability, controlled residual solvents, contaminant testing, and consistent assay results. A supplier may need to provide documentation covering more than 5 quality categories before commercial approval. Higher-standardization extracts are gaining interest because they simplify formulation consistency. Europe is expected to maintain stable expansion through 2035, supported by established herbal-product demand and increased preference for documented botanical ingredients rather than non-standardized raw powders.

Asia-Pacific

Asia-Pacific is estimated to account for approximately 48.7% of global Andrographis Paniculata Extract Market demand in 2026, making it the leading region. China, India, and Southeast Asian markets maintain established botanical cultivation, extraction capacity, herbal formulation industries, and traditional familiarity with Andrographis Paniculata. The 15%-50% category represents approximately 47.6% of regional product demand, while Treatment of Influenza accounts for approximately 31.2% of applications. Regional processors benefit from closer proximity to botanical raw material, helping reduce transport requirements and improve traceability.

Manufacturing scale is increasing as companies install extraction lines capable of processing several tonnes of dried botanical material during a production cycle. Advanced plants increasingly use more than 4 controlled stages covering extraction, filtration, concentration, purification, and drying. China remains particularly important because several supplied companies operate within the country's botanical ingredient industry. Asia-Pacific is expected to maintain its leading position through 2035, supported by raw-material availability, established technical expertise, export demand, and expanding higher-concentration extraction capacity.

Latin America

Latin America accounts for approximately 6.5% of global market demand in 2026. Brazil, Mexico, and other markets support demand through herbal products, natural wellness formulations, ingredient distributors, and traditional botanical applications. The 15%-50% category represents approximately 48.9% of regional product demand, while Treatment of Influenza accounts for approximately 28.7% of applications. Analgesic formulations contribute approximately 24.2%.

Regional manufacturers increasingly source standardized imports rather than conducting complete extraction domestically. Order sizes can begin below approximately 50 kilograms for smaller formulation companies, enabling gradual market participation. Demand through 2035 is expected to strengthen as botanical-product distribution expands and manufacturers increasingly request defined assay specifications. Suppliers offering flexible packaging sizes and multilingual technical documentation are positioned to serve small and medium regional customers more effectively.

Middle East & Africa

Middle East & Africa represents approximately 5.1% of global market demand in 2026. The 15%-50% category accounts for approximately 46.2% of regional product activity, while Treatment of Influenza contributes approximately 27.9% of applications. Demand is concentrated in major urban markets and among herbal-product distributors serving consumers seeking botanical formulations. High-purity 50%-98% extracts represent approximately 29.6% of regional demand and remain concentrated in premium products.

Supply-chain reliability is particularly important because much of the region depends on imported botanical extracts. Lead times can exceed approximately 4 weeks depending on origin, documentation, and transport conditions. Distributors therefore maintain safety inventories to prevent seasonal shortages. Market growth through 2035 is expected to remain positive as botanical-product availability expands, but supplier success will depend on consistent documentation, stable assay levels, and dependable international logistics.

List of Top Andrographis Paniculata Extract Companies

• Martin Bauer Group
• Sabinsa
• Bioprex
• Gurjar Phytochem
• Mother Herbs
• Pure and Green
• Guilin Layn Natural Ingredients
• Changzhou Natural Pharmaceutical
• Shaanxi Huike Botanical Development
• Hunan Zhengdi Biological
• Sichuan Hongyi
• Xi'an Changyue Phytochemistry
• Sichuan Zhonghong
• Guilin Sanling Biotech
• Shaanxi Tianrun
• Changsha LuYuan Bio-Tech

Top 2 Companies Market Share

Martin Bauer Group: Martin Bauer Group is estimated to represent approximately 14.7% of organized competitive presence among the supplied companies, supported by broad botanical ingredient capabilities, international distribution, extraction expertise, quality-control infrastructure, and relationships with formulation manufacturers. The 15%-50% category represents approximately 46.8% of overall product demand, providing a substantial market for standardized extract suppliers. Competitive differentiation increasingly depends on botanical identity verification, traceability, reproducible assay values, process efficiency, and the ability to supply multiple concentration specifications across international markets.

Sabinsa: Sabinsa is estimated to account for approximately 12.9% of organized competitive presence among the supplied companies, supported by botanical-standardization capabilities, ingredient development, analytical testing, and international commercial presence. The 50%-98% category represents approximately 32.7% of 2026 demand and provides substantial opportunity for suppliers capable of higher-level purification. Competitive positioning increasingly depends on active-compound standardization above approximately 50%, analytical documentation, controlled processing, and technical support for formulation customers seeking concentrated botanical ingredients.

Investment Analysis

Investment across the Andrographis Paniculata Extract Market is increasingly directed toward extraction efficiency, chromatographic purification, solvent recovery, vacuum concentration, spray drying, analytical laboratories, raw-material traceability, and controlled cultivation. The 50%-98% category represents approximately 32.7% of 2026 demand and is expected to approach approximately 38.4% by 2035, making high-purity processing an important investment area. Advanced plants increasingly use more than 4 purification stages and automated process monitoring to maintain consistent assay levels. Solvent-recovery systems can reclaim more than 80% of selected process solvents, lowering operating costs and improving environmental performance. Investments in analytical instrumentation also help manufacturers verify compound concentration before final release.

North America represents a strong downstream investment opportunity because regional demand is projected to expand at approximately 11.6% annually through 2035. Suppliers seeking access to premium customers increasingly invest in technical documentation, application support, warehousing, and local distribution rather than relying exclusively on bulk exports. Asia-Pacific remains attractive for upstream manufacturing because it represents approximately 48.7% of 2026 demand and contains extensive botanical raw-material supply. Investment opportunities therefore span cultivation, extraction, high-purity processing, analytical testing, packaging, and international distribution. Manufacturers that integrate more than 5 stages of the supply chain can improve traceability and reduce dependence on external processors.

New Product Development

New product development is increasingly focused on higher-standardization extracts with improved solubility, controlled particle size, lower residual solvents, and better batch consistency. Manufacturers are developing 50%-98% products using refined purification methods that can achieve target-compound concentrations above approximately 90%. Controlled drying processes can also reduce final moisture below approximately 5%, improving storage stability and powder flow. Particle-size management is becoming more important because uniform powders are easier to blend into downstream formulations. Producers increasingly provide multiple assay specifications from a common production platform, allowing customers to select concentration levels according to formulation requirements.

Lower-concentration product development remains active as manufacturers improve broad-spectrum extracts within the Less than 15% category. These products can preserve a wider botanical profile while benefiting from improved contaminant control and standardized raw-material sourcing. New development programs increasingly monitor more than 6 quality parameters before commercial release, including identity, assay, moisture, microbial quality, residual solvents, and heavy metals. Through 2035, product development is expected to emphasize higher purity, greater water compatibility, improved traceability, lower process residues, consistent color, controlled particle size, standardized concentration, and packaging designed to protect botanical stability during international transport.

Five Recent Developments

• March 2024: Botanical extract manufacturers increased adoption of multi-stage purification, enabling selected Andrographis Paniculata Extract grades to achieve active-compound concentrations above approximately 90% for high-standardization formulations.
• September 2024: Producers expanded raw-material traceability programs covering at least 3 supply stages, including cultivation, harvesting, and extraction, to improve consistency across commercial botanical batches.
• April 2025: Manufacturing facilities increasingly integrated solvent-recovery technologies capable of reclaiming more than approximately 80% of selected process solvents, improving extraction efficiency and lowering material consumption.
• November 2025: Quality-control programs expanded to more than 6 routine testing parameters as international buyers increased requirements for assay verification, microbial control, moisture, residual solvents, and contaminant screening.
• June 2026: High-concentration 50%-98% product development accelerated as manufacturers introduced improved purification and controlled drying processes targeting moisture levels below approximately 5% and more consistent powder characteristics.

Report Coverage

The Andrographis Paniculata Extract Market analysis covers industry conditions from 2026 through 2035 using 2025 as the historical baseline and incorporates the stated 10% CAGR. Product analysis includes Less than 15%, 15%-50%, and 50%-98%, while application coverage includes Hypoglycemic, Analgesic, Treatment of Dysentery, Treatment of Influenza, and Other. The 15%-50% category accounts for approximately 46.8% of 2026 demand, while Treatment of Influenza represents approximately 30.6%. The assessment examines extraction efficiency, botanical standardization, purification, active-compound concentration, quality control, solvent recovery, analytical testing, cultivation, raw-material traceability, high-purity processing, formulation demand, investment priorities, and new product development.

Regional coverage includes Asia-Pacific, North America, Europe, Latin America, and Middle East & Africa, with Asia-Pacific estimated to represent approximately 48.7% of global demand in 2026 and North America projected to expand approximately 11.6% annually through 2035. Competitive coverage includes Martin Bauer Group, Sabinsa, Bioprex, Gurjar Phytochem, Mother Herbs, Pure and Green, Guilin Layn Natural Ingredients, Changzhou Natural Pharmaceutical, Shaanxi Huike Botanical Development, Hunan Zhengdi Biological, Sichuan Hongyi, Xi'an Changyue Phytochemistry, Sichuan Zhonghong, Guilin Sanling Biotech, Shaanxi Tianrun, and Changsha LuYuan Bio-Tech. The assessment evaluates extraction-yield improvements near 20%, high-purity concentration above 90%, solvent recovery above 80%, moisture control below 5%, and increasing demand for standardized botanical ingredients across multiple supplied applications.